It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glutamatergic excitotoxicity is hypothesised to underlie synaptic loss in schizophrenia pathogenesis, but it is unknown whether synaptic markers are related to glutamatergic function in vivo. Additionally, it has been proposed that N-acetyl aspartate (NAA) levels reflect neuronal integrity. Here, we investigated whether synaptic vesicle glycoprotein 2 A (SV2A) levels are related to glutamatergic markers and NAA in healthy volunteers (HV) and schizophrenia patients (SCZ). Forty volunteers (SCZ n = 18, HV n = 22) underwent [11C]UCB-J positron emission tomography and proton magnetic resonance spectroscopy (1H-MRS) imaging in the left hippocampus and anterior cingulate cortex (ACC) to index [11C]UCB-J distribution volume ratio (DVR), and creatine-scaled glutamate (Glu/Cr), glutamate and glutamine (Glx/Cr) and NAA (NAA/Cr). In healthy volunteers, but not patients, [11C]UCB-J DVR was significantly positively correlated with Glu/Cr, in both the hippocampus and ACC. Furthermore, in healthy volunteers, but not patients, [11C]UCB-J DVR was significantly positively correlated with Glx/Cr, in both the hippocampus and ACC. There were no significant relationships between [11C]UCB-J DVR and NAA/Cr in the hippocampus or ACC in healthy volunteers or patients. Therefore, an appreciable proportion of the brain 1H-MRS glutamatergic signal is related to synaptic density in healthy volunteers. This relationship is not seen in schizophrenia, which, taken with lower synaptic marker levels, is consistent with lower levels of glutamatergic terminals and/or a lower proportion of glutamatergic relative to GABAergic terminals in the ACC in schizophrenia.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Whitehurst, Thomas 2
; Mansur Ayla 3 ; Statton Ben 4
; Berry Alaine 4 ; Quinlan, Marina 4 ; O’Regan Declan P 4
; Rogdaki, Maria 1
; Marques, Tiago Reis 5
; Rabiner Eugenii A 6
; Gunn, Roger N 3 ; Vernon, Anthony C 7
; Natesan Sridhar 8
; Howes, Oliver D 1
1 Hammersmith Hospital Campus, MRC London Institute of Medical Sciences, Imperial College London, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); Faculty of Medicine, Imperial College London, Institute of Clinical Sciences (ICS), London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Psychology and Neuroscience, King’s College London, Department of Psychosis Studies, Institute of Psychiatry, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); South London and Maudsley NHS Foundation Trust, London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839)
2 Hammersmith Hospital Campus, MRC London Institute of Medical Sciences, Imperial College London, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); Faculty of Medicine, Imperial College London, Institute of Clinical Sciences (ICS), London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
3 Hammersmith Hospital, Department of Brain Sciences, Imperial College London, The Commonwealth Building, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); Invicro, Burlington Danes Building, London, UK (GRID:grid.498414.4)
4 Hammersmith Hospital Campus, MRC London Institute of Medical Sciences, Imperial College London, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923)
5 Hammersmith Hospital Campus, MRC London Institute of Medical Sciences, Imperial College London, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); Psychology and Neuroscience, King’s College London, Department of Psychosis Studies, Institute of Psychiatry, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); South London and Maudsley NHS Foundation Trust, London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839)
6 Invicro, Burlington Danes Building, London, UK (GRID:grid.498414.4); King’s College London, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
7 King’s College London, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); King’s College London, MRC Centre for Neurodevelopmental Disorders, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
8 Hammersmith Hospital Campus, MRC London Institute of Medical Sciences, Imperial College London, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); Psychology and Neuroscience, King’s College London, Department of Psychosis Studies, Institute of Psychiatry, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)




